+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07252739

Study of Pembrolizumab Plus MK-1084 With or Without Additional Agents for Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation A Randomized Phase 2 Trial of Targeted Therapies in First-line Treatment

Led by Merck Sharp & Dohme LLC · Updated on 2026-09-02

140

Participants Needed

39

Research Sites

132 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of a medicine called MK-1084 in treating Non-Small Cell Lung Cancer NSCLC with a specific gene change known as KRAS G12C. This study aims to find out how many participants experience tumor shrinkage or disappearance while receiving this treatment. The study is a Phase 2 trial focused on advanced or metastatic nonsquamous NSCLC with this genetic mutation. Participants receive one of three treatments Pembrolizumab plus MK-1084 Pembrolizumab, MK-1084, and Cetuximab or Pembrolizumab, MK-1084, and sacituzumab tirumotecan sac-TMT. Pembrolizumab is given intravenously every 6 weeks, MK-1084 is taken orally, and Cetuximab or sac-TMT are given intravenously every 2 weeks depending on the assigned group. Rescue medications are also provided to reduce side effects like infusion reactions and mouth sores. During the study, participants undergo evaluations for side effects and tumor response at various time points, including up to approximately 84 months for long-term safety and effectiveness monitoring. Researchers assess dose-limiting toxicities, adverse events, and how many participants stop treatment because of side effects. Tumor response is measured using established criteria, and blood samples are collected to study MK-1084 levels. The total study duration extends until 2032, allowing for extended follow-up.

CONDITIONS

Brief Title

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here